SMPDL3B

Across TCGA pan-cancer cohorts, SMPDL3B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMPDL3B data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SMPDL3B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMPDL3B expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where SMPDL3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.352	0.899	<.001	24	view →
CCRCC	DFS	Tertile	IV	0.260	0.887	.024	6	view →
LSCC	DFS	Quartile	II,III,IV	0.577	0.932	.033	2	view →
LUAD	OS	Quartile	All	1.000	0.547	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMPDL3B–PDAC (DFS)

Open the PDAC breakdown →